Sale by Richard Murray of 12100 shares of Jounce Therapeutics

Jounce Therapeutics insider trading alert for sale of common stock by Richard Murray, CEO and President, on July 10, 2018. This event was filed by Jounce Therapeutics Inc with SEC on 2018-03-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Jounce Therapeutics Summary

Jounce Therapeutics (JNCE) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 112 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 271.89 M. Jounce Therapeutics conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 32.48 M outstanding shares of which 4.17 M shares are currently shorted by private and institutional investors with about 8.77 trading days to cover.
The company currently holds about 237.18 M in cash with (94.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.

Ownership Allocation (%)

Target Price Odds Analysis

Based on normal probability distribution, the odds of Jounce Therapeutics to move above current price in 30 days from now is about 1.2% (This Jounce Therapeutics probability density function shows the probability of Jounce Therapeutics Stock to fall within a particular range of prices over 30 days) .

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 112 people. more